PCSK9 Inhibition in Patients After Heart Transplantation: a Retrospective Review and Literature Analysis - Current Heart Failure Reports
Source : https://link.springer.com/article/10.1007/s11897-023-00604-2
Purpose of Review Following cardiac transplantation, patients have an increased risk of developing cardiac allograft vasculopathy and atherosclerotic cardiovascular disease. Therefore, aggressive lipid management is indicated. Some patients do not...
Summary: In our study, the 110 patients from literature review were added to a cohort of 7 similar patients from our institution for combined analysis. This report supports that PCSK9 inhibitors should be considered following cardiac transplantation when conventional medial therapy is not tolerated or ineffective.
Share
![Discovery of [5,5'-bibenzo[d][1,3]dioxol]-6-substituted amine derivatives as potent proprotein convertase subtilisin/kexin type 9 inhibitors - PubMed](https://static-content-prd.skipta.com/public/skipta/skipta-post/2023-05/pubmed-meta-image_207.png "Discovery of [5,5'-bibenzo[d][1,3]dioxol]-6-substituted amine derivatives as potent proprotein convertase subtilisin/kexin type 9 inhibitors - PubMed")
Discovery of [5,5'-bibenzo[d][1,3]dioxol]-6-substituted amine derivatives as potent proprotein convertase subtilisin/kexin type 9 inhibitors - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/37170061/
Proprotein convertase subtilisin/kexin type 9 (PCSK9) has emerged as a promising therapeutic target for the treatment of hyperlipidemia. In discovery of novel small molecules that interfere PCSK9/LDLR protein-protein interaction (PPI),...
Conclusions/Relevance: It is significant that molecules D28 and D29 exhibited potential for the treatment of hyperlipidemia in current in vitro investigations. Generally, lead compounds with novel structures were developed in the present study for further design of lipid-lowering molecules by targeting PCSK9/LDLR PPI.
Share
Inclisiran, Low-Density Lipoprotein Cholesterol and Lipoprotein (a) - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/37111334/
Dyslipidemia treatment is of major importance in reducing the risk of atherosclerotic cardiovascular disease (ASCVD), which is still the most common cause of death worldwide. During the last decade, a...
Conclusions: Inclisiran exerts a prolonged and significant LDL-C-lowering effect based on its unique mechanism of action. Some of the ORION trials have been completed confirming that inclisiran effectively reduced LDL-C in patients with elevated LDL-C, despite maximally tolerated statin therapy (±ezetimibe), in different clinical...
Share
Conclusions: HCRU within the first year of ASCVD diagnosis is substantial among patients with ASCVD and elevated Lp(a). Relatively higher rates of inpatient hospitalizations, increased LOS per hospitalization, and requirement of revascularization procedures within the first year of ASCVD index diagnosis were observed in patients with...
Share
Historical Review of the Use of Relative Risk Statistics in the Portrayal of the Purported Hazards of High LDL Cholesterol and the Benefits of Lipid-Lowering Therapy
The manner in which clinical trial investigators present their findings to healthcare providers and the public can have a substantial influence on their impact. For example, if a heart attack...
Conclusions/Relevance: We assert that the emphasis on RR coupled with insufficient disclosure of AR in the reporting of RCT outcomes has led healthcare providers and the public to overestimate concerns about high cholesterol and to be misled as to the magnitude of the benefits of cholesterol-lowering therapy. The goal of this review is to...
Share